A growing number of stem cell clinics treat a variety of illnesses and injuries, yet few have conducted the necessary clinical research to ensure safety and efficacy.
The authors highlight the importance of collaboration between scientists, regulators, patients and patient advocates in developing effective policies and practices for unproven stem cell-based intervention clinics.
The authors explore the different scientific values and priorities that should be considered in setting the policy agenda for effectively combating neglected tropical diseases (NTDs) and argue that researchers and physicians should participate in this process.
As his term progresses, President Trump will be faced with a large number of policy challenges, some of them requiring immediate science & technology expertise. In this Science Magazine article, the authors urge the president to consider the Office of Science & Technology Policy, the science advisor and the presidential S&T councils as vital resources that should be used early in the term to drive his policy agenda.
Kirstin R.W. Matthews, Kenneth M. Evans, Neal F. LaneFebruary 10, 2017
This study of biologists and physicists in the UK found that a majority of the respondents disagree with evolutionary biologist Richard Dawkins’ “celebrity scientist” outreach approach and believe his work misrepresents science and the scientific research process.
Elaine Howard Ecklund, Kirstin R.W. MatthewsOctober 10, 2016
In this first-ever survey of biologists and physicists in eight regions around the world, the authors analyze the religiosity of scientists or their perceptions of the science-faith interface. The study is published in the Aug. 31, 2016, issue of Socius: Sociologic Research for a Dynamic World.
Elaine Howard Ecklund, Kirstin R.W. Matthews, Steven W. LewisSeptember 1, 2016
This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.
Kirstin R.W. Matthews, Ana S. IltisNovember 4, 2015
While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.
Monica M. Matsumoto, Kirstin R.W. MatthewsAugust 4, 2015
This article analyzes the history of computing in electric power systems and why utilities persistently embraced analog technology before transitioning to digital computing machines: IEEE Annals of the History of Computing, July 13, 2015.
Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.